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Received May 26, 2014; accepted February 17, 2015AbstractIntracranial germ-cell tumors (GCTs) represent 10e15% of all pediatric brain tumors in East Asia. There is a wide histopathological
spectrum of intracranial GCTs. Germinomas and nongerminomatous GCTs are the two major classifications. It is difficult to distinguish different
subtypes of intracranial GCTs based solely on imaging studies, however, some tumor markers, such as a-fetoprotein or b-human chorionic
gonadotropin, are helpful for diagnosis. In this study we present the case of a 13-year-old girl with an intracranial mixed GCT containing a
hepatocellular carcinoma and germinoma without a primary liver tumor. Based on this unique pathological diagnosis, a series of treatments were
applied, including surgery for gross tumor removal, adjuvant radiotherapy, and chemotherapy. Long-term follow up indicates fair disease control.
Copyright © 2015 Elsevier Taiwan LLC and the Chinese Medical Association. All rights reserved.
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Intracranial germ-cell tumors (GCTs) represent approxi-
mately 2e4% of pediatric central nervous system neoplasms
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1726-4901/Copyright © 2015 Elsevier Taiwan LLC and the Chinese Medical Assincrease of incidences in East Asian countries such as Taiwan
and Japan.1,2 GCTs have been categorized into two groups,
namely, germinomas (60e70% of intracranial GCTs) and
nongerminomatous GCTs (NGGCTs), based on histologic
characteristics and the degrees of differentiation.1 Clinical
presentation of intracranial GCTs is often based on the loca-
tion and size of the tumor. There are three sites in which
intracranial GCTs commonly arise: the pineal, suprasellar, and
basal ganglia regions.1 In addition, intracranial GCTs can be
classified as having good, moderate, or poor prognosis, ac-
cording to Matsutani et al.3 Pure germinomas have the bestociation. All rights reserved.
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T). NGGCTs, however, are reported to have a poorer prog-
nosis than germinoma, even after standard treatment involving
combined chemotherapy (C/T) and R/T. Herein, we describe a
very rare case of a mixed GCT, composed of hepatocellular
carcinoma (HCC) and germinoma, which has never been re-
ported before.
2. Case Report2.1. History and examinationFig. 1. T1-weighted brain magnetic resonance imaging with contrast in (A)
coronal and (B) axial planes: a mixed cystic and solid tumor over the basal
ganglia with extension to bilateral lateral ventricles.A 13-year-old girl presented with congenital hypothyroid-
ism but was euthyroid due to regular thyroxine therapy. Her
symptoms began 1 month prior to her admission in May 2006
and included nausea, vomiting, and headaches. A diagnosis of
gastroenteritis had been made at another hospital, although her
symptoms persisted despite the respective treatment. During
that same period, she experienced a total weight loss of 4.5 kg,
and a 7000-mL increase in daily urine production was also
noted in the following days. On the day before her admission,
the patient lost consciousness several times; each episode
lasted for 1 hour. She was brought to our emergency depart-
ment in June 2006. Following admission, magnetic resonance
imaging (MRI) of her brain revealed an extensive mixed-solid
and cystic tumor extending from the left basal ganglia to the
bilateral anterior horns of the lateral ventricles, measuring
approximately 65 mm in maximum diameter (Fig. 1). There
was no evidence of seeding in other sites in the brain or spinal
column. The patient's serum levels of a-fetoprotein (AFP)
were markedly elevated to 20,095 ng/mL, whereas her b-
human chorionic gonadotropin levels were within a normal
range (<10 mIU/mL). Her antihepatitis B antibody was reac-
tive, and hepatitis B virus surface antigen as well as anti-
hepatitis C virus tests were all negative. Her liver biochemical
measurements, including liver transaminases, aspartate trans-
aminase and alanine transaminase, and alkaline phosphatase
levels were all within normal limits.2.2. Operation and pathologyBecause of obstructive hydrocephalus and increased intra-
cranial pressure, the patient underwent emergency surgery on
June 14, 2006. After craniotomy, the tumor was removed piece
by piece by a transcortical approach and near total tumor
removal was achieved. The pathology seemed to be a mixed
GCT, which included germinoma as well as HCC without
other components such as squamous epithelium, respiratory
epithelium, other teratomatous tissue, embryonal carcinoma,
choriocarcinoma, or yolk sac tumors (YSTs). The gross pa-
thology view of the tumor could not be obtained due to the
fragmented specimen provided. Microscopically, the germi-
noma tumor cells had large, centrally located nuclei, promi-
nent large eosinophilic nucleoli, as well as clear cytoplasm
(Fig. 2A). Lymphocytic infiltration was noted within the
tumor. Placental alkaline phosphatase (PLAP; Fig. 2B)
immunoreactivity was seen in the germinoma tumor cells. Theother tumor component showed tumor cells arranged in sinu-
soidal or trabecular patterns. The tumor cells were polygonal,
having a distinct cell border with a moderate amount of
eosinophilic granular cytoplasm. The nuclei were round to
ovoid, with discernible nucleoli (Fig. 2C). The tumor cells
were immunoreactive for cytokeratin, hepatocyte-specific an-
tigen (Fig. 2D), and AFP (Fig. 2E), but negative for PLAP.
However, an abdominal computed tomography scan and so-
nography did not reveal any evidence of a primary liver tumor
lesion. Most importantly, despite our pathologists' suggestion
that it was most likely derived from a teratoma, there was no
other teratoma component noted in the pathological
examination.2.3. Post-operative course and follow-upAdjuvant R/T and C/T were arranged. Adjuvant R/T was
planned with curative intent, and a tumor dose of 54 Gy was
Fig. 2. (A) Germinoma tumor component [hematoxylin and eosin (H&E) stain, 400]. (B) Immunoreaction for placental alkaline phosphatase (PLAP) in ger-
minoma tumor cells (anti-PLAP, 400). (C) Hepatocellular carcinoma component (H&E stain, 400). (D) Immunoreaction for hepatocyte-specific antigen in
hepatocellular carcinoma (hepatocyte-specific antigen, 400). (E) Immuno-reaction for AFP in hepatocellular carcinoma (AFP, 400).
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dimensional conformal technique in 27 fractions. Decreased
serum levels of AFP (349 ng/mL) were noted after the R/T.
Subsequent C/T, involving a regimen of vinblastine, bleomy-
cin, etoposide (VP-16), and cisplatin (VBEP),4 was adminis-
tered on a monthly basis for 11 months. Symptoms of
increased intracranial pressure gradually improved, and
follow-up serum levels of AFP were within a normal range
(<20 ng/mL) following the third course of C/T. Medications
for congenital hypothyroidism and diabetes insipidus were
regularly administered to the patient after she was admitted.
She experienced generalized toniceclonic seizures several
times following the surgery, which were controlled with val-
proic acid. There was no residual tumor in the follow-up brain
image. The most recent brain MRI, taken on March 16, 2011,
showed typical post-operative changes and tissue loss in the
left frontal region 5 years after the surgery (Figs. 3A and 3B).
Although the disease was in complete remission,complications such as panhypopituitarism, epilepsy, adjust-
ment disorder, major depression, developmental retardation,
and mild mental retardation were noted. Specifically, there was
a significant decline in neurocognitive function. The patient
was evaluated using the Wechsler Intelligence Scale for
Children both before the diagnosis and 4 years after the sur-
gery; the Full Scale IQ scores were 106 and 69, respectively.
She has been receiving long-term occupational therapy and
physical therapy since all clinical treatments were completed.
3. Discussion
Compared with Western countries, there is a high incidence
of intracranial GCTs in Asian countries. In a single medical
center in Taiwan, Wong et al5 reported that intracranial GCTs
comprise 14% of all primary pediatric brain tumors. The
subtypes of intracranial GCTs, however, vary in histology. The
World Health Organization classifies intracranial GCTs as
Fig. 3. T1-weighted brain magnetic resonance imaging with contrast in (A)
coronal and (B) axial planes: 5 years’ follow up, status after the surgery, ra-
diation therapy, and chemotherapy.
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(mature, immature, and malignant transformations), embry-
onal carcinoma, choriocarcinoma, YST, and mixed GCT. In
this paper, we present a very rare case of mixed GCT con-
taining both germinoma and HCC cells in the brain. Teilum6
presumed that extragonadal GCTs are derived from germ-
cell progenitors that have migrated abnormally during em-
bryonic development and have given rise to extragonadal
GCTs. However, one of the possible origins of HCC might be
from monodermal teratomas, which are predominantly
composed of one tissue type and are most commonly seen in
the ovaries. Ovarian monodermal teratomas include three main
types, namely, struma ovarii, ovarian carcinoid tumors, and
tumors with neural differentiation.2,7 Other than monodermal
teratoma, hepatoid YSTwas considered another explanation in
this case. There are several histological variants of YSTs, one
of which is hepatoid differentiation. According to Roth and
Talerman,8 there must be >50% component of YST for the
diagnosis of variant YST to be tenable. Although both HCC
and YST have a positive response to AFP stain, throughout the
whole pathology findings, no YST morphological component
was noted in our case. Besides, intracranial YST possesses the
potential for neuraxis dissemination and very poor survival,
with a median interval of approximately 1 year even after
multidisciplinary treatments. However, our patient has had
long-term survival for >5 years. Hence, the diagnosis of YST
with hepatoid differentiation is less likely.Germinomas are highly sensitive to R/T. Although there is
not yet a uniform protocol for irradiation doses and volumes,
lower doses and limited volumes (avoiding craniospinal irra-
diation) with or without systemic C/Tare the currently accepted
standards for nondisseminated diseases. Yen et al9 reported that
low-dose R/Twithout C/T is satisfactory for patients who do not
have risk factors. Our patient had mixed GCT without spinal
seeding, and we treated her with a standard dose (54 Gy) to a
limited field of 1.5 cm surrounding the tumor bed, rather than
using extended fields such as craniospinal irradiation. Adjuvant
C/T was also given in combination with VBEP,4 which is the
standard C/T regimen for GCTs in our hospital, given its
acceptable efficacy and toxicity. The long-term follow up
showed a complete remission without seeding or recurrence for
>5 years. Aside from the positive response to R/T seen in
germinomas, HCC is also known to have good sensitivity to R/T
and is thus treated with proportionate doses. Higher R/T doses
result in better median survival rates. Dawson et al10 reported a
median survival of>16.4 months in HCC patients who received
R/T doses of 70 Gy.11 However, R/T is not regularly used in
primary HCC due to low tolerance of normal liver tissue to
irradiation, as well as nearby organs such as the intestines.
Eliminating these problems, HCC in the brain is believed to
respond well to R/T. However, there were several critical organs
located near the tumor mentioned in this case, including the
pituitary gland, the optic chiasm, and vessels in the circle of
Willis. Hence, we could not administer the maximum R/T dose
described by Dawson et al's study.10 To balance the treatment
response and R/T-related complications, a tumor dose of 54 Gy
was delivered.
In conclusion, this is the first report about primary HCC
arising from the central nervous system. However, the real
origin remains in question. Although there were no typical
pathology findings, both monodermal teratoma and hepatoid
YST might be possible explanations. Our patient has achieved
satisfying disease control after the combined treatment of
surgery, C/T, and R/T.
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